Aripiprazole lauroxil (BioDeep_00000826510)
代谢物信息卡片
化学式: C36H51Cl2N3O4 (659.3256426)
中文名称: 阿立哌唑月桂酯
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=C1C=C(C=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl
InChI: InChI=1S/C36H51Cl2N3O4/c1-2-3-4-5-6-7-8-9-10-16-35(43)45-28-41-33-27-30(19-17-29(33)18-20-34(41)42)44-26-12-11-21-39-22-24-40(25-23-39)32-15-13-14-31(37)36(32)38/h13-15,17,19,27H,2-12,16,18,20-26,28H2,1H3
描述信息
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents
D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants
C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:90930
- KEGGdrug: D10364
- PubChem: 49831411
- DrugBank: DB14185
- ChEMBL: CHEMBL2219425
- CAS: 1259305-29-7
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Roger W Sommi, Bhaskar Rege, Angela Wehr, Sejal Faldu, Yangchun Du, Peter J Weiden. Aripiprazole Lauroxil Dosing Regimens: Understanding Dosage Strengths and Injection Intervals.
CNS spectrums.
2022 06; 27(3):262-267. doi:
10.1017/s1092852920002072. [PMID: 33267924] - Deanna L Kelly, Amy Claxton, Ilda Bidollari, Yangchun Du. Analysis of prolactin and sexual side effects in patients with schizophrenia who switched from paliperidone palmitate to aripiprazole lauroxil.
Psychiatry research.
2021 08; 302(?):114030. doi:
10.1016/j.psychres.2021.114030. [PMID: 34118485] - Peter J Weiden, Yangchun Du, Lisa von Moltke, Angela Wehr, Marjie Hard, Morteza Marandi, David P Walling. Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.
CNS drugs.
2020 09; 34(9):961-972. doi:
10.1007/s40263-020-00745-1. [PMID: 32621071] - Sarah Farwick, Magali B Hickey, Gwen Jacobs, Sejal P Faldu, Jennifer Vandiver, Peter J Weiden. Best Practices for Aripiprazole Lauroxil Administration: From Formulation Development to Injection Technique.
Journal of psychiatric practice.
2019 03; 25(2):82-90. doi:
10.1097/pra.0000000000000376. [PMID: 30849056] - Marjie L Hard, Angela Y Wehr, Yangchun Du, Peter J Weiden, David Walling, Lisa von Moltke. Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia.
Journal of clinical psychopharmacology.
2018 Oct; 38(5):435-441. doi:
10.1097/jcp.0000000000000921. [PMID: 30015676] - Marjie L Hard, Angela Y Wehr, Brian M Sadler, Richard J Mills, Lisa von Moltke. Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole Lauroxil.
European journal of drug metabolism and pharmacokinetics.
2018 Aug; 43(4):461-469. doi:
10.1007/s13318-018-0488-4. [PMID: 29943125] - Yiying Sun, Xiaoyan Lu, Yunyun Gai, Chunjie Sha, Guangyi Leng, Xiucheng Yang, Wanhui Liu. LC-MS/MS method for the determination of the prodrug aripiprazole lauroxil and its three metabolites in plasma and its application to in vitro biotransformation and animal pharmacokinetic studies.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2018 Apr; 1081-1082(?):67-75. doi:
10.1016/j.jchromb.2018.02.011. [PMID: 29510329] - Robert Risinger, Marjie Hard, Peter J Weiden. A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil.
Psychopharmacology bulletin.
2017 08; 47(3):26-34. doi:
NULL. [PMID: 28839337] - Henry A Nasrallah, Ralph Aquila, Arielle D Stanford, Hasan H Jamal, Peter J Weiden, Robert Risinger. Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil.
Psychopharmacology bulletin.
2017 08; 47(3):35-43. doi:
NULL. [PMID: 28839338] - Marjie L Hard, Richard J Mills, Brian M Sadler, Angela Y Wehr, Peter J Weiden, Lisa von Moltke. Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model.
CNS drugs.
2017 Jul; 31(7):617-624. doi:
10.1007/s40263-017-0447-7. [PMID: 28597226] - Henry A Nasrallah, John W Newcomer, Robert Risinger, Yangchun Du, Jacqueline Zummo, Anjana Bose, Srdjan Stankovic, Bernard L Silverman, Elliot W Ehrich. Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia.
The Journal of clinical psychiatry.
2016 Nov; 77(11):1519-1525. doi:
10.4088/jcp.15m10467. [PMID: 27574838] - Morten Rohde, Niels M Rk, Anders E Håkansson, Klaus G Jensen, Henrik Pedersen, Tina Dige, Erling B J Rgensen, René Holm. Biological conversion of aripiprazole lauroxil - An N-acyloxymethyl aripiprazole prodrug.
Results in pharma sciences.
2014; 4(?):19-25. doi:
10.1016/j.rinphs.2014.04.002. [PMID: 25756003]